Heart surgeons endorse xenotransplantation

A survey of attitudes among heart surgeons shows most are supportive of xenotransplantation.

According to a new survey, more than 80% of heart surgeons believe the potential acceptance of xenotransplantation would be high if it can demonstrate reasonable results [1]. The study comes as researchers around the world are seeking new ways to increase the supply of organs to younger heart patients.

Longevity.Technology: A scarcity of donors means that many young heart disease patients will never receive life-saving transplants. Xenotransplantation is one of the most promising avenues to increase organ supply, but uncertainty remains around the retrovirus risks or how surgeons would greet the prospect if it became available.

Recent years have seen a significant improvement in mortality rates for heart transplants however challenges remain [2]. Transplantation for young children is hampered by the scarcity of donors, waiting list mortality rates remain high with one of the biggest challenges being a lack of support options for patients with single ventricle physiology [3]. However, advances in xenotransplantation in which live tissue is transplanted from pigs to humans suggest it could provide a viable alternative [4].

Back in June last year we reported that researchers from Harvard and eGenesis had used  CRISPR to genetically remove retroviruses to make pigs organs viable for human transplantation; and that eGenesis announced it has raised $100 million in a series B funding round, led by venture capital firm Fresenius Medical Care, one of the world’s leading companies in end stage and chronic kidney disease treatment.

Now, as the Xeno market progresses, this study attempted to understand attitudes among heart surgeons towards the procedure. To do so they sent a Likert scale anonymous survey to members of the Congenital Heart Surgeons Society and the Pediatric Heart Transplant Society.

In total, 92 surgeons responded from the CHS and 42 responded from the PTC. Both groups showed a high acceptance (88% and 81% respectively) assuming results could be shown to be similar to those of cardiac allotransplantation.

Those numbers came down considerably when asked to assume results were shown to be inferior to cardiac allotransplantation, with only 41% of surgeons from the CHS and 17% of surgeons from the PTC, saying they would support it. A third of CHS and half of PTC respondents preferred primary cardiac xenotransplantation for hypoplastic left heart syndrome if it has similar outcomes to allotransplantation and there was no waiting list time.

Research into xenotransplantation is still ongoing, but this study shows clinical acceptance would not be a major barrier as long as studies show it can offer comparative results to existing methods.

[1] https://journals.sagepub.com/doi/abs/10.1177/2150135120916744
[2] https://srtr.transplant.hrsa.gov/annual_reports/2017/Heart.aspx
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827130/
[4] https://www.scientificamerican.com/article/baboons-survive-for-half-a-year-after-heart-transplants-from-pigs/

Image by Sasin Tipchai from Pixabay
Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of Crowd Longevity a digital investment platform for international investors and Longevity start-ups launching in 2020.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Latest articles

Epigenetic regulation of protein homeostasis following DNA damage

Recent study identifies critical regulator of protein biosynthesis recovery and homeostasis required for Longevity. Unresolved DNA damage caused by intrinsic and environmental factors accumulates during...

Deep Longevity and Longenesis collaborate to clock aging

Start the clock to stop the clock – centralised data will aid Longevity research.  Deep Longevity, which engages in the development of explainable AI systems...

Big Brother approach to accelerate preclinical studies

Tracked.bio develops AI computer vision system that tracks flies and mice to reduce man-hours and increase data collected in Longevity studies. A Danish start-up aims...

Astellas to acquire iota Biosciences

Following an R&D collaboration that began last year, Japanese pharma Astellas has announced it will acquire bioelectronics firm iota in $304m deal. Last year's R&D...